DUBLIN--(BUSINESS WIRE)--The "Lipodystrophy Syndrome (LS)- Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Lipodystrophy Syndrome (LS) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
As per Elaine Chiquette et. Al., the estimated prevalence of diagnosed Lipodystrophy Syndrome (LS) was 3.07 cases/million (95% confidence interval [CI], 2.30-4.02), 0.23 cases/million (95% CI, 0.06-0.59) and 2.84 cases/million (95% CI, 2.10-3.75) for generalized lipodystrophy (GL) and partial lipodystrophy (PL), respectively.
According to Orphanet registry, Primary lipodystrophies prevalence has been estimated at less than 1 case in 100,000.
This research estimates that the prevalent population of Lipodystrophy Syndrome (LS) will significantly change during the study period [2016-2027].
Current therapies prevent or ameliorate the comorbidities of Lipodystrophy Syndrome (LS). At present, Myalept (Bristol-Myers Squibb) (recombinant human methionyl leptin) is the only drug approved specifically for lipodystrophy. It is approved in the United States as an adjunct to diet for treatment of metabolic complications in patients with generalized lipodystrophy.
Key players such as Ionis Pharmaceuticals, Zydus Cadila and many others are involved in developing therapies for Lipodystrophy Syndrome (LS). Expected launch of emerging therapies such as Volanesorsen (Ionis Pharmaceuticals), Lipaglyn (Zydus Cadila) and some other are expected to change the treatment landscape of Lipodystrophy Syndrome (LS) in upcoming years.
- Ionis Pharmaceuticals
- Zydus Cadila
- Bristol-Myers Squibb
Key Topics Covered
1. Report Introduction
2. Lipodystrophy Syndrome (LS) Market Overview at a Glance
3. Disease Background and Overview: Lipodystrophy Syndrome (LS)
4. Epidemiology and Patient Population
5. Lipodystrophy Syndrome (LS): Country-Wise Epidemiology
6. Treatments & Medical Practices
7. Marketed Drug
8. Emerging Therapies
9. Lipodystrophy Syndrome (LS) Market Size
10. 7MM: Country-Wise Market Analysis
11. Market Drivers
12. Market Barriers
13. Report Methodology
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/lvrh6l/lipodystrophy?w=4